See more : Aarti Pharmalabs Limited (AARTIPHARM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Eiger BioPharmaceuticals, Inc. (EIGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eiger BioPharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Miliboo Société anonyme (ALMLB.PA) Income Statement Analysis – Financial Results
- Rathdowney Resources Ltd. (RATHF) Income Statement Analysis – Financial Results
- Nongshim Co., Ltd. (004370.KS) Income Statement Analysis – Financial Results
- Nihon Tokushu Toryo Co., Ltd. (4619.T) Income Statement Analysis – Financial Results
- MS Industrie AG (MSAG.DE) Income Statement Analysis – Financial Results
Eiger BioPharmaceuticals, Inc. (EIGR)
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.77M | 13.48M | 12.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 24.00K | 1.84M | 745.00K | 645.00K | 486.00K | 54.00K | 41.00K | 23.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.75M | 11.65M | 11.40M | -645.00K | -486.00K | -54.00K | -41.00K | -23.00K | -11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 99.85% | 86.38% | 93.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.33M | 75.28M | 64.44M | 41.59M | 51.79M | 37.09M | 29.52M | 33.01M | 21.96M | 22.68M | 16.93M | 13.31M | 4.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.20M | 29.11M | 23.90M | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Other Expenses | 87.00K | -963.00K | 46.49M | -12.00K | -15.00K | -12.00K | 186.00K | -277.00K | 5.00K | -835.00K | 25.00K | 147.00K | 152.00K |
| Operating Expenses | 87.54M | 104.39M | 88.34M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Cost & Expenses | 87.56M | 106.22M | 89.08M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Interest Income | 2.21M | 1.08M | 158.00K | 704.00K | 2.07M | 997.00K | 410.00K | 0.00 | 65.00K | 118.00K | 69.00K | 35.00K | 7.00K |
| Interest Expense | 5.47M | 4.13M | 3.56M | 3.59M | 3.41M | 2.33M | 1.52M | 690.00K | 2.30M | 741.00K | 59.00K | 108.00K | 1.12M |
| Depreciation & Amortization | 750.00K | 119.00K | 46.65M | 1.34M | 2.54M | 54.00K | 41.00K | 23.00K | 504.00K | 153.00K | 67.00K | 64.00K | 73.00K |
| EBITDA | -68.74M | -92.62M | -76.94M | -60.81M | -66.36M | -50.06M | -40.92M | -46.40M | -33.82M | -33.02M | -19.80M | -15.70M | -5.79M |
| EBITDA Ratio | -435.81% | -686.90% | -249.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.79M | -92.74M | -76.94M | -62.15M | -68.90M | -51.05M | -41.52M | -46.12M | -42.18M | -33.02M | -19.96M | -15.95M | -6.03M |
| Operating Income Ratio | -455.12% | -687.78% | -633.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.17M | -4.01M | 43.09M | -2.90M | -1.35M | -1.34M | -928.00K | -967.00K | -2.23M | -835.00K | -127.00K | 74.00K | -965.00K |
| Income Before Tax | -74.96M | -96.75M | -33.85M | -65.05M | -70.25M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.09M | -15.87M | -6.99M |
| Income Before Tax Ratio | -475.22% | -717.54% | -278.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 6.00K | 23.00K | 64.00K | 3.58M | 3.39M | 985.00K | 1.67M | 390.00K | 2.31M | -153.00K | -12.00K | 101.00K | 1.28M |
| Net Income | -74.96M | -96.78M | -33.92M | -68.63M | -73.64M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.00M | -15.72M | -6.99M |
| Net Income Ratio | -475.26% | -717.71% | -279.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| EPS Diluted | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| Weighted Avg Shares Out | 1.48M | 1.39M | 34.63M | 29.88M | 24.43M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
| Weighted Avg Shares Out (Dil) | 1.48M | 1.39M | 34.63M | 29.88M | 24.50M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
Analysts' Downgrades for January, 28th (ABBV, ACHC, ALGN, AMAT, ARGKF, ARWR, ATRC, ATVI, BGNE, BPFH)
Source: https://incomestatements.info
Category: Stock Reports